http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2238772-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-02 |
| filingDate | 2002-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d341c719395e790b602306735ee30781 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f802e4d96e9b947aa3183678e10eccb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ca1e7e74289a6a0281d7b00e6e795ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e58dfef2a851c28db715acf65cbb3bee |
| publicationDate | 2004-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2238772-C2 |
| titleOfInvention | Method for treating patients for respiratory organ sarcoidosis |
| abstract | FIELD: medicine. n SUBSTANCE: method involves applying 1-2 courses of millimetric bandwidth radiation therapy in treating sternum zone at thymus gland projection point 40 min long daily during 20 days as monotherapy or in combination with prednisolone given at a dose of 10 mg every day within the millimetric therapy course. The millimetric therapy course involves applying electromagnetic noise radiation in 3.8-5.6 mm bandwidth distinguished by total specific noise power in the wavelength bandwidth within the limits of 1.0-4.0 mcW/cm 2 and noise frequency distribution spectrum nonuniformity not exceeding ±3dB. When treating intrathoracic lymph nodes sarcoidosis, the millimetric therapy is applied as monotherapy. It is combined with prednisolone given at a dose of 10 mg in the cases of pulmonary sarcoidosis and intrathoracic lymph nodes sarcoidosis. The treatment is carried out under photofluorographic and general clinical examination control in 10 procedures and in 1.5 months after finishing the first millimetric therapy course. The second millimetric therapy course is administered in 1.5 months after finishing the first one. Decision concerning its administration necessity is taken on the basis of control photofluorographic and general clinical examination results. n EFFECT: enhanced effectiveness of treatment. n 4 cl, 2 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2530623-C1 |
| priorityDate | 2002-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.